According to a study by Xue et al., a patient with R/R classical Hodgkin’s lymphoma (cHL) was treated with low doses and repeated infusions of CD19- and CD30-redirected CAR-Ts which resulted in the prolonged progression-free survival (PFS) of the patients without any severe treatment-related toxicities (50). Here, CD19 is linked to classic Hodgkin lymphoma.